Abstract
G protein-coupled receptors (GPCRs) constitute several membrane proteins that are turned on by hormones and neurotransmitters to trigger cellular signaling pathways. GPCRs have been targeted in the development of several drugs but the therapeutic potential of these proteins remains underutilized. Most drugs to date have targeted the class A, or the rhodopsin family of GPCRs, but recently the Class B, i.e., the secretin family of G protein receptors has been targeted for the treatment of metabolic diseases such as diabetes mellitus. Class B G protein-coupled receptors (GPCRs) have also been targeted for managing several clinical conditions such as diabetes mellitus, bone disorders, malignancies, neurodegeneration, cardiovascular diseases, neuropsychiatric disorders, etc. In this article, we review the medicinal chemistry and potential clinical role of targeting GPCRs with a special emphasis on cardiovascular pharmacology.
Keywords: Beta-arrestin, cardiovascular diseases, diabetes, G protein-coupled receptor, glucagon, heart failure, hypertrophy, ligand, rhodopsin, secretin.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:G Protein-Coupled Receptors – Potential Roles in Clinical Pharmacology
Volume: 12 Issue: 1
Author(s): Megan Kypreos, Teesta Banerjee and Debabrata Mukherjee
Affiliation:
Keywords: Beta-arrestin, cardiovascular diseases, diabetes, G protein-coupled receptor, glucagon, heart failure, hypertrophy, ligand, rhodopsin, secretin.
Abstract: G protein-coupled receptors (GPCRs) constitute several membrane proteins that are turned on by hormones and neurotransmitters to trigger cellular signaling pathways. GPCRs have been targeted in the development of several drugs but the therapeutic potential of these proteins remains underutilized. Most drugs to date have targeted the class A, or the rhodopsin family of GPCRs, but recently the Class B, i.e., the secretin family of G protein receptors has been targeted for the treatment of metabolic diseases such as diabetes mellitus. Class B G protein-coupled receptors (GPCRs) have also been targeted for managing several clinical conditions such as diabetes mellitus, bone disorders, malignancies, neurodegeneration, cardiovascular diseases, neuropsychiatric disorders, etc. In this article, we review the medicinal chemistry and potential clinical role of targeting GPCRs with a special emphasis on cardiovascular pharmacology.
Export Options
About this article
Cite this article as:
Kypreos Megan, Banerjee Teesta and Mukherjee Debabrata, G Protein-Coupled Receptors – Potential Roles in Clinical Pharmacology, Cardiovascular & Hematological Agents in Medicinal Chemistry 2014; 12 (1) . https://dx.doi.org/10.2174/187152571201141201093751
DOI https://dx.doi.org/10.2174/187152571201141201093751 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Personalized Diabetes and Cancer Medicine: A Rationale for Anti-Diabetic Nutrition (Bitter Melon) in a Supportive Setting
Current Cancer Therapy Reviews Inpatient Diabetes Management in Non-ICU Settings: Evidence and Strategies
Current Diabetes Reviews A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects
Current Neuropharmacology Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting
CNS & Neurological Disorders - Drug Targets Right Heart Catheterization Through Persistent Left Superior Vena Cava, an Extremely Rare Procedure and Review of Current Literature
Current Cardiology Reviews Central Amylin Signaling and the Regulation of Energy Homeostasis
Current Pharmaceutical Design Preface
Current Nutrition & Food Science Use of Paediatric Xylometazoline Nasal Drop is not a Child’s Play in Hypertensive Patients on Bisoprolol: A Case Report
Current Drug Safety Oxidative Stress and the JNK Pathway are Involved in the Development of Type 1 and Type 2 Diabetes
Current Molecular Medicine Hydroethanolic Extract of <i>Lampaya Medicinalis</i> Phil. (<i>Verbenaceae</i>) Decreases Proinflammatory Marker Expression in Palmitic Acid-exposed Macrophages
Endocrine, Metabolic & Immune Disorders - Drug Targets Serum Hepcidin, the Hepcidin/Ferritin Ratio and the Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Editorial (Thematic Issue: Sex, Environment, Physical Activity, Diet, and Obesity in Cardiovascular Disease Risk)
Current Vascular Pharmacology Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature
Current Psychopharmacology Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Editorial [Hot topic:Beta Cell Imaging - Why we need it and what has been Achieved (Executive Editor: Martin Gotthardt)]
Current Pharmaceutical Design Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents QSAR Studies of PTP1B Inhibitors: Recent Advances and Perspectives
Current Medicinal Chemistry L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Letters in Drug Design & Discovery Editorial [Concurrent Blood Pressure, Glycemic and Lipid Control for the Prevention of Vascular Complications of Type II Diabetes Mellitus: A Long Overdue Objective?]
Current Vascular Pharmacology